The report

The State of Kanna, 2026.

Kanna went from obscure succulent to supplement-aisle contender fast, and the market grew faster than the honesty did. This is our running data report on where it actually stands: what brands disclose, which formats and prices dominate, and what the science does and does not support. Every number here is computed from the same verified catalog that powers our reviews, so it stays honest and current.

14
products tracked
12
brands
86%
disclose potency
7/12
publish batch COAs

The headline findings

  1. 01

    86% of the products we track state a real potency figure. That is higher than the category's reputation suggests, because we only track products worth tracking; the wider shelf is far murkier.

  2. 02

    Only 7 of 12 brands clear both bars that matter to a buyer: a disclosed potency number AND a published, batch-matched lab report.

  3. 03

    Capsules are the most common format we track, but no single format dominates; kanna in 2026 is a genuinely multi-format category.

  4. 04

    The entire modern human evidence base is 4 core studies and 3 clinical trials, the largest of which enrolled 37 people. Promising, and still very small.

1. The transparency problem

The single defining feature of the kanna market is that most products will not tell you how strong they are. A milligram number means nothing without a potency figure behind it: 25 mg of a standardized extract is worlds apart from 25 mg of a raw powder or a mystery blend. We score every product on whether it states a verifiable potency, and every brand on whether it backs that up with a batch-matched COA.

86%

state a real potency figure

Among products we consider worth tracking. The broader unbranded shelf, smoke-shop jars and marketplace no-names, discloses far less.

7 of 12

brands publish a batch COA

The brands that clear our Approved bar. The rest either disclose potency without a public COA, or neither.

Full product-by-product detail is in the Kanna Transparency Index.

2. What the market looks like

By format

  • Capsules4
  • Tinctures3
  • Powders3
  • Extract tablets2
  • Chews / gum1
  • Gummies1

By price

  • Affordable3
  • Mid-range8
  • Premium3

Where brands sell

  • Direct8
  • Amazon3
  • Direct + Amazon1

No single format owns kanna in 2026. That is unusual for a young supplement and it tells you the category is still finding its shape: some buyers want a studied capsule, some want a pleasant gummy, and a traditionalist minority still wants raw plant. On effect profile, the products we track skew 6 balanced, 5 calm, 3 uplift, which matches how kanna actually works: dose-dependent, from calm at the low end to uplift higher up.

3. What the science actually shows

The honest headline: the human research on kanna is promising, consistent on mechanism, and very small. It rests on 4 core studies and 3 clinical trials, most of them on one standardized extract (Zembrin), several with industry involvement, and the largest enrolled just 37 people. That is enough to describe how kanna works and that it is well-tolerated at studied doses. It is not enough to claim it treats any condition.

  • Harvey et al., 2011PMID 21798331 ↗

    Identified kanna's dual mechanism, serotonin-reuptake inhibition (5-HT transporter) and PDE4 inhibition, in vitro.

  • Terburg et al., 2013PMID 23903032 ↗

    A single 25 mg dose of standardized extract reduced amygdala reactivity to fearful faces on fMRI (n=16).

  • Nell et al., 2013PMID 23441963 ↗

    A 3-month placebo-controlled trial (n=37) found 8 mg and 25 mg/day were well-tolerated, with no significant changes in vitals or blood chemistry.

  • Chiu et al., 2014PMID 25389443 ↗

    A 3-week randomized study (n=21) reported improved cognitive set flexibility and executive function vs placebo.

Every study, in full, with DOIs, is in the Kanna Research Library.

The 2026 verdict

Kanna in 2026 is a real category built on a thin but genuine foundation. The mechanism is well-characterized, the safety signal at studied doses is reassuring, and a handful of transparent brands are doing it right. The problem is not the plant; it is the disclosure. Most of the market still sells a milligram number with no potency behind it, and buyers have almost no way to compare products on the one thing that determines whether they will feel anything.

Our read: the brands that will win the next few years are the ones publishing a potency figure and a batch COA today, because that is the exact gap every serious buyer is trying to close. Until disclosure becomes the norm, the single most useful skill for a kanna shopper is reading the label for a real alkaloid number, and walking past the ones that do not have one.

Published 2026-07-02 by the Kanna Reviews editorial desk. Figures reflect the products and brands we actively track and are not a census of the entire market. Editorial and independent; no brand pays for placement or scoring. Not medical advice. Kanna raises serotonin, so do not combine it with SSRIs, SNRIs, MAOIs, or other serotonergic medications without medical advice, and avoid it in pregnancy.